We would like to discuss "Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis". The serological responses, breakthrough infections, and clinical relapse of IBD patients treated with biological drugs after SARS-CoV-2 immunization were the subject of a thorough study and meta-analysis. The total seroconversion rate following SARS-CoV-2 immunization in IBD patients receiving biological therapy is high, according to Dai et al. In IBD patients receiving biological therapy, the overall rate of breakthrough infections and the rate of clinical recurrence were both low.